Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
7.50    -0.40 (-5.06%)
Bid:
7.00
Ask:
8.00
Spread: 1.00 (14.286%)
Market Cap: £474.94m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Allergy Thera. News

Allergy Therapeutics gets US FDA approval for peanut vaccine trial
26 Jan 2022

Allergy Therapeutics gets US FDA approval for peanut vaccine trial

Allergy Therapeutics gets US FDA approval for peanut vaccine trial

TRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps
13 Jan 2022

TRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps

TRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps

UK shareholder meetings calendar - next 7 days
15 Nov 2021

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger
27 Oct 2021

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

Allergy Therapeutics reports positive results from field study
25 Oct 2021

Allergy Therapeutics reports positive results from field study

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate ...

Allergy Therapeutics shares jump on positive G309 trial results
25 Oct 2021

Allergy Therapeutics shares jump on positive G309 trial results

Allergy Therapeutics shares jump on positive G309 trial results

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises
23 Sep 2021

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results
13 Sep 2021

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results